Willkie Advises on Teva Pharmaceutical’s $5 Billion Acquisition of Ratiopharm

March 18, 2010

Willkie is serving as lead antitrust and competition counsel to Teva on the transaction.

On March 18, Willkie client Teva Pharmaceutical Industries Ltd. announced that it has entered into a definitive agreement to acquire Ratiopharm GmbH, Germany's second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of $5 billion. Willkie is serving as lead antitrust and competition counsel to Teva on the transaction.  Willkie partners William Rooney (NY) and David Tayar (Paris), and special counsel David Park, are handling the matter.

Headquartered in Israel, Teva is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients.